Main Facts: A Milestone in Research Funding
In a significant development for the oncology community, the metastatic breast cancer (MBC) advocacy landscape has reached a new financial zenith. Dr. Kelly Shanahan, President of the organization, recently announced that the 2025 grant cycle has successfully secured funding for 14 new research grants, totaling $3.55 million.
This announcement marks a pivotal moment for a grassroots organization that has punched well above its weight class since its inception. By prioritizing high-impact, innovative research, the organization continues to bridge the gap between laboratory discovery and clinical application for patients who have few options remaining. The 14 recipients, whose identities will be unveiled in a forthcoming formal announcement, were selected based on their potential to fundamentally alter the treatment trajectory for metastatic patients.
Chronology: From Humble Roots to a $41 Million Legacy
The trajectory of this organization is a testament to the power of patient-led advocacy. Since the inception of its grant-giving program in 2020, the organization has maintained an aggressive and consistent funding schedule.
- 2020: The inaugural grant cycle established the foundational commitment to funding research that specifically targets metastatic disease—an area historically underfunded compared to early-stage breast cancer research.
- 2021–2023: Through the height of global health challenges, the organization maintained its momentum, expanding its reach and deepening its relationships with research institutions across the United States.
- 2024: The cumulative total of research funding approached the $40 million mark, solidifying the organization’s status as a primary driver of independent MBC research.
- 2025: With the addition of the $3.55 million cohort, the organization has now awarded approximately 230 grants, bringing the total investment in life-saving research to nearly $41 million.
This progression highlights a remarkable operational feat: the organization functions primarily through a volunteer board, the vast majority of whom are living with MBC themselves. This creates a unique "patient-scientist" feedback loop where the decision-makers are also the primary beneficiaries of the research being funded.
Supporting Data: The Impact of Grassroots Philanthropy
The $41 million figure is more than just a metric; it represents a comprehensive portfolio of clinical trials, translational research, and laboratory studies. In the oncology world, where federal funding cycles can be cumbersome and slow, private, targeted grants allow researchers to pivot quickly to emerging discoveries.
The organization’s model relies on a lean, efficient administrative structure. By keeping overhead low, they ensure that the maximum possible percentage of donor contributions goes directly to the bench. This efficiency has allowed them to support:
- Early-stage clinical trials: Filling the gap for experimental therapies that have not yet reached Phase III, providing patients with access to potentially life-extending treatments.
- Translational research: Moving successful lab results into clinical environments.
- Supportive care research: Improving the quality of life for those living with chronic metastatic disease, acknowledging that "living with" is as important as "surviving."
Official Responses and Strategic Initiatives
Dr. Kelly Shanahan’s leadership during this cycle has been characterized by both fiscal expansion and organizational introspection. In her recent letter to supporters, she outlined three strategic pillars for the coming year:
1. The "Groundswell" Advocacy Campaign
Beyond research funding, the organization is pivoting toward legislative influence. The "Groundswell" initiative is a virtual advocacy event designed to lower the barrier to entry for patients and their families. By facilitating remote communication between constituents and their elected representatives, the organization aims to keep metastatic cancer at the forefront of the legislative agenda. The focus remains on policy changes that accelerate drug approval, increase federal research funding, and address the socioeconomic barriers to clinical trial participation.
2. Organizational Evolution
The Board of Directors is currently undergoing a period of growth. With the integration of new members, the organization is poised to launch several new initiatives aimed at community engagement. As part of this transition, they have announced an upcoming subscriber survey. The objective is to refine communication channels, ensuring that patients, researchers, and donors receive information tailored to their specific needs, effectively optimizing the organization’s reach.
3. The Personal Dimension of Leadership
The strength of the organization lies in its authenticity. Dr. Shanahan’s transparency regarding her own health journey—noting that her cancer has progressed and that she is actively seeking a new clinical trial—underscores the urgency of their mission. Her plan to travel from California to Nashville to participate in a trial highlights the geographic disparities in healthcare that many MBC patients face. Her message is one of resilient pragmatism: "That’s the life of an MBC girl." By sharing these personal stakes, she bridges the gap between the board room and the patient room, reinforcing the idea that this fight is not academic—it is personal.
Implications: The Future of Metastatic Care
The implications of this $41 million investment are far-reaching. As the organization looks toward the remainder of 2025, several trends are likely to emerge:
The Decentralization of Clinical Trials
Dr. Shanahan’s journey to Nashville is a symptom of a larger issue in oncology: the centralization of top-tier clinical trials in a few major metropolitan hubs. As the organization grows, there is an increasing push to advocate for "trial accessibility," which includes travel support and the integration of decentralized trial models that allow patients to receive care closer to home while remaining under the guidance of elite research centers.
The Power of Patient-Led Advocacy
The success of this organization serves as a blueprint for other disease-specific advocacy groups. By proving that a volunteer-led board can successfully manage tens of millions of dollars in research funding, they are changing the landscape of medical philanthropy. The implication is that patients are no longer just passive participants in their care; they are active investors in their own survival.
Strengthening the Community Fabric
The upcoming survey and the call for community engagement represent a move toward a more "digitally-integrated" patient community. In the digital age, patient advocacy is no longer limited by physical proximity. Through social media, webinars, and virtual advocacy events, the organization is building a global network of patients who can share resources, support, and real-world data.
Conclusion: A Call to Action
The recent funding announcement is a moment of celebration, but it is also a call to action. As the organization prepares to reveal the 14 new awardees, they invite the public to remain engaged. Whether through participating in the Groundswell campaign, completing the upcoming survey, or simply staying informed through their social channels, the community’s involvement is the engine that keeps this work moving forward.
For Dr. Shanahan and the thousands of patients she represents, the mission is clear: to transform metastatic breast cancer from a terminal diagnosis into a chronic, manageable, and eventually curable condition. With $41 million invested and a clear vision for the future, the organization is not just funding grants—it is buying time, creating hope, and ensuring that no patient has to walk this path alone.
For those interested in connecting with the community or learning more about the upcoming grant announcements, please keep an eye on the organization’s official newsletter and social media platforms. For inquiries regarding personal advocacy or to reach out to the President’s office, please contact [email protected].
About the Author
